根据公告内容，公司拟使用自有资金及金融机构回购专项借款，以集中竞价交易方式回购社会公众股 份，预计回购金额区间为 6000 万元至 1.2 亿元，回购价格上限为 23.98 元 / 股，回购期限为董事会审议 通过之日起 12 个月。此次回购股份将用于员工持股计划或股权激励、转换公司可转债，旨在进一步完 善公司治理结构，绑定核心团队利益，同时优化资本结构，增强发展韧性。 公告显示，2026 年 2 月 2 日，步长制药顺利完成首次回购。本次共回购股份 217.6 万股，占公司总股本 的 0.21%，回购价格区间为 16.75 元 / 股至 17.12 元 / 股，累计支付资金 3675.79 万元(不含交易费用)。 值得关注的是，本次实际回购价格显著低于 23.98 元 / 股的价格上限，体现出公司在回购操作中的高效 性与审慎性，实现了资金使用效率的最大化。 在资金保障方面，步长制药已与中国农业银行股份有限公司菏泽牡丹支行签署专项借款合同，获得 1 亿 元 3 年期回购专项贷款，结合公司充裕的自有资金，为后续回购计划的推进提供了充足的资金支持。 回购释放多重积极信号 兼顾短期市值维稳与长期战略发展 近期，步长制 ...

Core Viewpoint - Recently, Buchang Pharma has gained market attention for its innovation in drug development, capital market returns, and commitment to public welfare, showcasing the company's responsibility and dedication in the pharmaceutical industry [1] Innovation Drug Pipeline - Buchang Pharma has made significant advancements in its innovation drug pipeline, covering three major areas: biopharmaceuticals, traditional Chinese medicine, and chemical drugs [2] - The company is accelerating the application of its first Class 1 new drug, Epoetin Alfa, targeting renal anemia and chemotherapy-induced anemia, which could fill a gap in the domestic long-acting EPO market valued at 15 billion [2] - The first biosimilar drug, Adalimumab injection, is under review, targeting multiple autoimmune diseases with substantial market potential [2] - The company is advancing its Class 1 biopharmaceutical BC001 for late-stage gastric cancer and has several targeted cancer drugs in critical clinical development stages [2][4] Traditional Chinese Medicine and Chemical Drug Expansion - In traditional Chinese medicine, the company has completed Phase II clinical trials for its Qi-tonifying granules and is set to start Phase II/III trials for its heart failure treatment granules in May 2025 [4] - In the chemical drug sector, Buchang Pharma has launched 17 new generic drugs in 2023, including products that target a 20 billion market for antiviral drugs and expand its muscle relaxant market [4] - The company has successfully renewed contracts for exclusive products in the 2025 National Medical Insurance Directory, with total sales exceeding 10.3 billion in the first three quarters [4] Shareholder Returns - Buchang Pharma has established a stable return mechanism for investors, with cumulative dividends reaching 7.948 billion and share buybacks totaling 1.744 billion since its listing [5] - In 2025, the company has repurchased 6.6206 million shares, with a total repurchase amount nearing 100 million, demonstrating confidence in its future development [5] Corporate Social Responsibility - Since its inception, Buchang Pharma has adhered to its mission of "creating health for humanity," actively engaging in social responsibility through the "Together, Build China's Heart" initiative for 18 years [6] - The initiative has expanded from congenital heart disease to various medical fields, providing comprehensive medical assistance to over 1 million patients [6] - The company has contributed nearly 33 billion in taxes nationwide, supporting regional economic development [6] Future Outlook - The chairman of Buchang Pharma, Zhao Tao, emphasized the company's commitment to innovation-driven development and social responsibility, aiming to lead industry growth and create greater social value [7]

Group 1 - The flu activity in China is on the rise, with a peak expected between mid-December and early January, leading to increased demand for antiviral and symptomatic treatment drugs, especially among children [1] - Bank securities report indicates that antiviral drugs are the main treatment method, with good expected efficacy; various traditional Chinese medicines and antipyretics are also available to alleviate symptoms during the illness [1] - Data from Meituan shows that since November, the overall order volume for specific flu medications has increased by over 100%, with orders for Oseltamivir granules rising by over 85% and for Baloxavir increasing by over 110% [1] Group 2 - Hainan Huhuwawa Pharmaceutical Group's Oseltamivir products have performed well, with capsules approved for production and stable market supply for the prevention and treatment of influenza A and B [3] - The company has developed a dry suspension that received drug registration certification in September, addressing dosage challenges for young children aged two and above [3] - The core product, Pediatric Lung Heat Cough and Asthma Granules, has been included in national treatment guidelines and health insurance directories, enhancing its market presence [3] Group 3 - Huhuwawa Pharmaceutical emphasizes research and innovation as a core driver for development, continuously enhancing R&D efforts in the pediatric medication sector [4] - The company has increased investment in R&D for pediatric drugs, with ongoing projects targeting infectious diseases, functional dyspepsia, allergic diseases, and adenoid hypertrophy [4]